Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8659715 | Heart, Lung and Circulation | 2018 | 10 Pages |
Abstract
In our trial-length, 5-year, and 10-year models, the co-therapy was not a cost-effective alternative; however, as follow-up was extended to lifetime, the co-therapy became a cost-effective treatment compared with the simvastatin monotherapy in patients with histories of ACS.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ziyad S. PhD, Jeff Jianfei BPharm, PhD, Abdullah BPharm, Nawaf MS, PhD, Hilal BPharm,